Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panobinostat plus midostaurin maintenance after allogeneic stem cell transplantation for FLT3-ITD AML
NL-OMON29431Phase 2Recruiting
- Sponsor
- HOVON
- Start
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of panobinostat and midostaurin in acute myeloid leukemia (AML) (3 cohorts), sponsored by HOVON. Primary endpoint: Dose-limiting toxicity. Started Dec 2017; status: recruiting.
02
Drugs
panobinostatmidostaurin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NL-OMON29431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON29431.